Introduction Executive Summary Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Late Stage Products (Phase III) • Comparative Analysis Tafasitamab: Morphosys • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis Drug Name: Company Name • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early stage products (Phase I/II) • Comparative Analysis LOXO-305: Loxo Oncology • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Companies Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Products Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Unmet Needs Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Market Drivers and Barriers Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Future Perspectives and Conclusion Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Analyst Views Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Companies Appendix

Table 1 Total Products for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Novartis • Celldex Therapeutics • PersonGen BioTherapeutics • Loxo Oncology • Kite Pharma • Bio-Path Holdings • MEI Pharma/Kyowa Kirin • MorphoSys • Beijing Mabworks Biotech